Novo Nordisk and Eli Lilly Compete in India's Booming Obesity Drug Market

Rising Demand for Obesity Drugs in India

• 📈 Demand for weight-loss drugs in India has significantly increased, leading to intense competition between rivals Novo Nordisk and Eli Lilly.
• 📊 Research firm Pharmarack indicates that sales of Eli Lilly's Mounjaro, launched in March, doubled from May to June, reaching nearly 88,000 units sold and over $3 million in value.
• 🚀 Novo Nordisk sold approximately 1,800 units of its drug Wegovy shortly after its late June launch.

Market Growth and Contributing Factors

• 🌍 The Indian obesity market has experienced a fivefold growth since 2021, now valued at $73 million.
• 💰 Factors such as affordability and a growing willingness to try new obesity treatments have propelled this market expansion.
• ⚠️ The Lancet highlights a global rise in obesity and diabetes, with India ranking among the top three countries for high obesity rates.

Competitive Landscape and Future Outlook

• 🔑 Semaglutide, the active ingredient in Wegovy, already holds a two-thirds share in the Indian market, with Novo Nordisk selling oral versions for diabetes since 2022.
• ⚖️ However, semaglutide is set to lose patent protection in India next year, opening the door for generic drug manufacturers to produce more affordable versions of Wegovy.
• 🌐 India is emerging as a critical battleground for pharmaceutical companies in the global obesity drug market.